If I did see this correctly, page-106

GC - 'tapping LW' for some extra cash was a source of much discussion earlier in the year, and didn't help the SP much, even on the back of results achieved in the P2 trial. In the end however, NEU found another way to finance with LW still involved as a major holder. I took a lot of confidence from that as an investor. In terms of potential partnerships, NEU has been fairly open about the fact that discussions have been going on for some time (late 16? possibly, definitely since early 17), can only suggest that nothing serious was ever going to develop until FDA approval for P3 occured. Do believe the company needs to make a statement soon regarding potential partnership to keep the momentum going, not in any hurry myself personally, but it has been a little quiet of late, be nice of NEU to check in.